NEW YORK, Nov. 11 (GenomeWeb News) - Orchid Biosciences reported a slight drop in revenues for the quarter ended Sept. 30, accompanied by shrinking R&D expenses and net losses.

The company's total quarterly revenues of $11.8 million were down from its third-quarter 2002 revenues of $13.3 million, which included $886,000 in revenues from the Life Sciences product business it sold in December 2002.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.